NCT00834405已完成1 期
A Relative Bioavailability, Parallel Study of Leflunomide 20 mg Tablets Under Non-Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 2
- 主要终点
- Cmax - Maximum Observed Concentration - Metabolite A77 1726 in Plasma
研究概览
简要总结
The objective of this study is to compare the relative bioavailability of leflunomide 20 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of ARAVA 20 mg tablets (Aventis) in healthy, adult, non-smoking subjects [females (who are unable to become pregnant) and vasectomized males] under non-fasting conditions.
详细描述
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects selected for this study will be non-smokers at least 18 years of age. Females must be physically unable to become pregnant. Males must be vasectomized. Weight of the subjects shall not be more than 20% ± from normal for height and body frame (Metropolitan Life, 1993, Height, Weight, Body Chart).
- •Each subject shall be given a general physical examination within 21 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
- •Each female subject will be given a serum pregnancy test as part of the pre-study screening process.
- •Adequate blood and urine samples should be obtained within 21 days before beginning of the first period and at th eend of the trial for clinical laboratory measurements.
- •Clinical laboratory measurements will include the following:
- •Hematology: hematocrit, hemoglobin, red blood cell count, platelets, white blood cell count (with differential).
- •Clinical chemistry: creatinine, BUN, glucose, SGOT/AST, SGPT/ALT, bilirubin, and alkaline phosphatase.
- •Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells.
- •HIV Screen: pre-study only.
- •Hepatitis-B, C Screen: pre-study only.
- •Drugs of Abuse Screen: pre-study and at check-in before dosing.
- •Subjects will be selected if all above are normal.
排除标准
- •Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or recent serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study.
- •Subjects whose clinical laboratory test values are greater than 20% outside the normal range may be retested. if the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
- •Subjects who have a history of allergic responses to the class of drug being tested should be excluded from the study. Subjects who have a history of allergic responses to cholestyramine should be excluded from the study.
- •All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at check-in before dosing. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.
- •Subjects should not have donated blood and/or plasma for at least 30 days prior to the first dosing of the study.
- •Subjects who have taken any investigational drug within 30 days prior to the first dosing of the study will not be allowed to participate.
- •Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study will not be allowed to participate.
- •All female subjects will be screened for pregnancy at check-in. Subjects with positive or inconclusive results will be withdrawn from the study.
- •Male subjects who are physically able to father a child will not be allowed to participate. Male subjects must be vasectomized (at least 3 months) with medical verification.
- •Subjects who smoke or use tobacco in any form will not be eligible to participate in the study. Three months abstinence is required.
- •Subjects who are unable to tolerate multiple venipuncture will be excluded.
- •Subjects who have taken any product containing leflunomide within 180 days of dosing will not be allowed to participate in this study.
研究组 & 干预措施
Leflunomide
Experimental
Leflunomide 20 mg Tablet
干预措施: Leflunomide 20 mg Tablets (Drug)
Arava®
Active Comparator
Arava® 20 mg Tablet
干预措施: ARAVA® 20 mg tablets (Drug)
结局指标
主要结局
Cmax - Maximum Observed Concentration - Metabolite A77 1726 in Plasma
时间窗: Blood samples collected over 72 hour period
Bioequivalence based on Cmax
AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours Post-dose (Per Participant) - Metabolite A77 1726
时间窗: Blood samples collected over 72 hour period
Bioequivalence based on AUC0-72
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting ConditionsPsoriatic ArthritisRheumatoid ArthritisNCT00946686Sandoz52
已完成
1 期
Leflunomide 20 mg Tablets Under Fasting ConditionsHealthyNCT00834418Teva Pharmaceuticals USA84
尚未招募
不适用
Bioequivalence Study of 20 mg Leflunomide Film-coated Tablets in Healthy Thai VolunteersBioequivalence Study of 20 mg Leflunomide Film-coated Tablets in Healthy Thai VolunteersTCTR20180531002All Research Co., Ltd.38
已完成
不适用
Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting ConditionsHealthyNCT00778115Ranbaxy Laboratories Limited26
已完成
1 期
Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)HyperlipidemiaNCT01353404Samyang Biopharmaceuticals Corporation24